A Phase I, Randomized, DoubleBlind Placebo-Controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Inhaled Doses (MAD) of AZD7624 to Healthy Subjects and Patients With COPD
Phase of Trial: Phase I
Latest Information Update: 01 Apr 2016
At a glance
- Drugs AZD 7624 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors AstraZeneca
- 09 Dec 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 10 Sep 2014 Planned number of patients changed from 90 to 42 as reported by ClinicalTrials.gov record.
- 10 Sep 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.